AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2487803 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (20 mg)
Number of subjects: 0
Study 2487803 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (100 mg)
Number of subjects: 0
Study 2487803 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg) + Captopril (50 mg)
Number of subjects: 0
Study 775145 — intervention group
Group type: EXPERIMENTAL
Intervention: ampicillin‐cloxacillin (Rectocillin) 1 g/day
Number of subjects: 0
Study 775145 — intervention group
Group type: COMPARATOR
Intervention: ampicillin (AB‐PC) 1 g/day
Number of subjects: 0
Study 31996367 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN+MTX
Number of subjects: 120
Study 31996367 — intervention group
Group type: COMPARATOR
Intervention: MTX-TT
Number of subjects: 120
Study 31996367 — intervention group
Group type: EXPERIMENTAL
Intervention: ETN administered first line
Number of subjects: 120
Study 31094901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vortioxetine 17 mg
Number of subjects: 55
Study 31094901 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 55
Study 28067119 — intervention group
Group type: EXPERIMENTAL
Intervention: ATV 400 mg daily (switch)
Number of subjects: 50
Study 28067119 — intervention group
Group type: COMPARATOR
Intervention: ATV/r 300/100 mg daily (control)
Number of subjects: 50
Study 28067119 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 50
Study 25659357 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 31
Study 25659357 — intervention group
Group type: COMPARATOR
Intervention: Control (only primary closure)
Number of subjects: 31
Study 24169735 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial pacing (%AP)
Number of subjects: 396
Study 22526538 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg d-amphetamine
Number of subjects: 36
Study 22526538 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg d-amphetamine
Number of subjects: 36
Study 22526538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19237720 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient mailings containing an educational pamphlet, fecal occult blood test kit, and instructions for scheduling screening.
Number of subjects: 21860
Study 19237720 — intervention group
Group type: COMPARATOR
Intervention: Electronic reminders to physicians during office visits.
Number of subjects: 21860
Study 19237720 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic reminders to physicians for patients with 3 or more primary care visits.
Number of subjects: 21860
Study 19237720 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient mailings and physician reminders for detection of adenomas.
Number of subjects: 21860
Study 17692718 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 0.5 mg QD
Number of subjects: 758
Study 17692718 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 2.0 mg BID
Number of subjects: 758
Study 17692718 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide inhalation suspension (BIS) 1.0 mg BID
Number of subjects: 758
Study 17692718 — intervention group
Group type: COMPARATOR
Intervention: Budesonide DPI 400 microg BID (active reference arm)
Number of subjects: 758
Study 17692718 — intervention group
Group type: EXPERIMENTAL
Intervention: All BIS dosages
Number of subjects: 758
Study 15334776 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood transfusion
Number of subjects: 2561
Study 15334776 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical intervention
Number of subjects: 2561
Study 15334776 — intervention group
Group type: EXPERIMENTAL
Intervention: Past use of glass syringes
Number of subjects: 2561
Study 15334776 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of risk factors
Number of subjects: 2561
Study 15334776 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjects younger than 46 years of age
Number of subjects: 2561
Study 15476998 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured education
Number of subjects: 30
Study 15476998 — intervention group
Group type: COMPARATOR
Intervention: Standard nursing care
Number of subjects: 30
Study 11704494 — intervention group
Group type: EXPERIMENTAL
Intervention: Active low-intensity pulsed ultrasound (US) at 30 mW/cm² for 20 min/day, 5 days/week, over 6 weeks
Number of subjects: 15
Study 11704494 — intervention group
Group type: COMPARATOR
Intervention: Inactive ultrasound (US) treatment
Number of subjects: 15
Study 9140518 — intervention group
Group type: EXPERIMENTAL
Intervention: CR challenge preceded by D.p. challenge (CR2)
Number of subjects: 12
Study 9140518 — intervention group
Group type: COMPARATOR
Intervention: CR challenge preceded by sham challenge (CR1)
Number of subjects: 12
Study 9140518 — intervention group
Group type: EXPERIMENTAL
Intervention: CR2
Number of subjects: 12
Study 8433424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancrod
Number of subjects: 28
Study 8433424 — intervention group
Group type: COMPARATOR
Intervention: Heparin
Number of subjects: 28
Study 3660329 — intervention group
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acids supplementation (2.880 g/day for 12 weeks)
Number of subjects: 44
Study 3660329 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 44
Study 29614582 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium tetragenous viable bacteria tablets
Number of subjects: 234
Study 29614582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 28801420 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-monopolar anodal transcranial direct current stimulation during upper limb motor training involving virtual reality
Number of subjects: 0
Study 28801420 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation during upper limb motor training involving virtual reality
Number of subjects: 0
Study 26208402 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood victimization (physical assault, sexual abuse)
Number of subjects: 2500
Study 26208402 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood victimization (sleep problems)
Number of subjects: 2500
Study 26208402 — intervention group
Group type: COMPARATOR
Intervention: Health risk behaviors and mental health problems
Number of subjects: 2500
Study 24010901 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobi-C cervical artificial disc (TDR)
Number of subjects: 330
Study 24010901 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 330
Study 21621252 — intervention group
Group type: EXPERIMENTAL
Intervention: Escalating doses of omega-3 PUFA (1 to 8 g daily over 24 weeks)
Number of subjects: 30
Study 21621252 — intervention group
Group type: COMPARATOR
Intervention: Aspirin and clopidogrel
Number of subjects: 30
Study 18502301 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced care including additional time with practice nurse and support from a link worker and diabetes-specialist nurse
Number of subjects: 1486
Study 18502301 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1486
Study 16789351 — intervention group
Group type: EXPERIMENTAL
Intervention: Performance feedback
Number of subjects: 0
Study 16789351 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 12952151 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance exercise group
Number of subjects: 34
Study 12952151 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait exercise group
Number of subjects: 34
Study 12952151 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 10980764 — intervention group
Group type: EXPERIMENTAL
Intervention: Foscarnet sodium and ganciclovir sodium as therapy for newly diagnosed CMV retinitis
Number of subjects: 0
Study 9004108 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril/Diltiazem ER
Number of subjects: 62
Study 1333071 — intervention group
Group type: EXPERIMENTAL
Intervention: 71.5 Gy in 52 fractions of 1.375 Gy given twice a day (hyperfractionated radiotherapy)
Number of subjects: 36
Study 1333071 — intervention group
Group type: COMPARATOR
Intervention: 65 Gy in 26 fractions of 2.5 Gy each (conventional radiotherapy)
Number of subjects: 36
Study 3882307 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine, 1 to 3 mg/day
Number of subjects: 42
Study 3882307 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine, 0.1 to 0.3 mg twice a day
Number of subjects: 42
Study 3882307 — intervention group
Group type: COMPARATOR
Intervention: Clonidine withdrawal
Number of subjects: 42
Study 3882307 — intervention group
Group type: COMPARATOR
Intervention: Guanfacine withdrawal
Number of subjects: 42
Study 31271210 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief cognitive behavioral therapy for insomnia (bCBTi)
Number of subjects: 54
Study 31271210 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual for MDD and/or PTSD
Number of subjects: 54
Study 31271210 — intervention group
Group type: EXPERIMENTAL
Intervention: bCBTi
Number of subjects: 54
Study 28751176 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic reminder condition
Number of subjects: 46581
Study 28751176 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction condition
Number of subjects: 46581
Study 28751176 — intervention group
Group type: EXPERIMENTAL
Intervention: Commitment condition
Number of subjects: 46581
Study 28751176 — intervention group
Group type: COMPARATOR
Intervention: Usual care condition
Number of subjects: 46581
Study 26184510 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD stage 3B-5
Number of subjects: 1011
Study 26184510 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR <45 ml/min/1.73 m(2)
Number of subjects: 1011
Study 26184510 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD stage 2-3
Number of subjects: 1011
Study 26184510 — intervention group
Group type: EXPERIMENTAL
Intervention: eGFR loss
Number of subjects: 1011
Study 26184510 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD equations (CG/BSA, BIS1, LM-rev)
Number of subjects: 1011
Study 25052243 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (75 mg)
Number of subjects: 30
Study 25052243 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (40 mg)
Number of subjects: 30
Study 25052243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22210240 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline HADS‐A score
Number of subjects: 137
Study 19534770 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel rehabilitation strategy consisting of an initial home exercise programme followed by higher intensity outpatient exercise classes.
Number of subjects: 600
Study 19534770 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitative care as provided by the hospital or recommended by the orthopaedic surgeon.
Number of subjects: 600
Study 19534770 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel rehabilitation strategy
Number of subjects: 600
Study 19534770 — intervention group
Group type: COMPARATOR
Intervention: Usual rehabilitative care
Number of subjects: 600
Study 17288694 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily (QD)
Number of subjects: 684
Study 17288694 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg QD
Number of subjects: 684
Study 17288694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 684
Study 17288694 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg QD
Number of subjects: 684
Study 15354280 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 2 mg twice daily
Number of subjects: 1348
Study 15354280 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg twice daily
Number of subjects: 1348
Study 15354280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1348
Study 15354280 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 2 mg and 6 mg
Number of subjects: 1348
Study 15354280 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod
Number of subjects: 1348
Study 12060615 — intervention group
Group type: EXPERIMENTAL
Intervention: Adoptive immunotherapy (AIT) with tumor-associated lymphocytes (TALs) plus low-dose cisplatinum/5-fluorouracil chemotherapy
Number of subjects: 44
Study 12060615 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (control group)
Number of subjects: 44
Study 10102433 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab (0.03 to 3.0 mg/kg)
Number of subjects: 28
Study 10102433 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 10102433 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab (1- or 3-mg/kg IV dose)
Number of subjects: 28
Study 7480850 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training program (10-week duration)
Number of subjects: 46
Study 7480850 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (control)
Number of subjects: 46
Study 2263920 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound (A)
Number of subjects: 18
Study 2263920 — intervention group
Group type: COMPARATOR
Intervention: Placebo ultrasound (B)
Number of subjects: 18
Study 2263920 — intervention group
Group type: COMPARATOR
Intervention: No therapeutic intervention (C)
Number of subjects: 18
Study 7459895 — intervention group
Group type: EXPERIMENTAL
Intervention: Single large dose of misonidazole
Number of subjects: 21
Study 7459895 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple smaller doses of misonidazole
Number of subjects: 21
Study 7459895 — intervention group
Group type: COMPARATOR
Intervention: Irradiation only (Control)
Number of subjects: 21
Study 6677075 — intervention group
Group type: EXPERIMENTAL
Intervention: Stagefright anxiety
Number of subjects: 0
Study 6677075 — intervention group
Group type: EXPERIMENTAL
Intervention: Monotonous concentration
Number of subjects: 0
Study 6677075 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control
Number of subjects: 0
Study 31842921 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-marrow autologous mesenchymal stem cells (MSC)
Number of subjects: 20
Study 31842921 — intervention group
Group type: COMPARATOR
Intervention: P-PRP
Number of subjects: 20
Study 30393990 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal testing with universal leucoreduction
Number of subjects: 10000000000
Study 30393990 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing only first-time donors with universal leucoreduction
Number of subjects: 10000000000
Study 30393990 — intervention group
Group type: EXPERIMENTAL
Intervention: No testing with universal leucoreduction
Number of subjects: 10000000000
Study 30393990 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy of leucoreduction
Number of subjects: 10000000000
Study 25664595 — intervention group
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic acid (TUDCA) 1 g twice daily for 54 weeks
Number of subjects: 34
Study 25664595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 25664595 — intervention group
Group type: EXPERIMENTAL
Intervention: TUDCA
Number of subjects: 34
Study 24944242 — intervention group
Group type: EXPERIMENTAL
Intervention: V2R agonist (0.2 mg desmopressin)
Number of subjects: 10
Study 24944242 — intervention group
Group type: EXPERIMENTAL
Intervention: V2R antagonist (30 mg tolvaptan)
Number of subjects: 10
Study 24944242 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 24944242 — intervention group
Group type: EXPERIMENTAL
Intervention: All conditions (including placebo)
Number of subjects: 10
Study 22113708 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (300 mg day(‐1)) for 1 month
Number of subjects: 50
Study 22113708 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vitamin E)
Number of subjects: 50
Study 20711481 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 53
Study 20711481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 18519471 — intervention group
Group type: EXPERIMENTAL
Intervention: Constantly low sucrose intake (lowest 10%)
Number of subjects: 543
Study 18519471 — intervention group
Group type: EXPERIMENTAL
Intervention: Average sucrose intake (80%)
Number of subjects: 543
Study 18519471 — intervention group
Group type: COMPARATOR
Intervention: Constantly high sucrose intake (highest 10%)
Number of subjects: 543
Study 18519471 — intervention group
Group type: EXPERIMENTAL
Intervention: Low and average sucrose intake groups
Number of subjects: 543
Study 15084928 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopic donor nephrectomy (HALDN)
Number of subjects: 59
Study 15084928 — intervention group
Group type: COMPARATOR
Intervention: Pure retroperitoneoscopic donor nephrectomy (RLDN)
Number of subjects: 59
Study 15084928 — intervention group
Group type: EXPERIMENTAL
Intervention: Both HALDN and RLDN
Number of subjects: 59
Study 11698565 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg daily for 5 years)
Number of subjects: 11064
Study 11698565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11064
Study 9219046 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (mean dose of 166 mg/day)
Number of subjects: 30
Study 9219046 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (mean dose of 310 mg/day)
Number of subjects: 30
Study 7524888 — intervention group
Group type: EXPERIMENTAL
Intervention: Busulphan (1 mg/kg orally QID days -7 to -4) and cyclophosphamide (60 mg/kg IV days -3 and -2) chemotherapy
Number of subjects: 69
Study 7524888 — intervention group
Group type: COMPARATOR
Intervention: Post-transplant G-CSF
Number of subjects: 69
Study 3109575 — intervention group
Group type: EXPERIMENTAL
Intervention: Attempted induction of labour (group 1)
Number of subjects: 409
Study 3109575 — intervention group
Group type: COMPARATOR
Intervention: No intervention (group 2)
Number of subjects: 409
Study 29569449 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia crown placement
Number of subjects: 40
Study 29569449 — intervention group
Group type: COMPARATOR
Intervention: Non-restorative therapy
Number of subjects: 40
Study 29231295 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at Zusanli (ST 36) and Feishu (BL 13) applied 30 min before the operation till the end of the operation
Number of subjects: 80
Study 29231295 — intervention group
Group type: COMPARATOR
Intervention: Control group (no electroacupuncture)
Number of subjects: 80
Study 24148208 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week group self-management intervention addressing proactive coping strategies
Number of subjects: 106
Study 24148208 — intervention group
Group type: COMPARATOR
Intervention: group education intervention
Number of subjects: 106
Study 22492213 — intervention group
Group type: EXPERIMENTAL
Intervention: DaTscan imaging
Number of subjects: 273
Study 22492213 — intervention group
Group type: COMPARATOR
Intervention: Control group (no imaging)
Number of subjects: 273
Study 20972912 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT delivered in a psychiatric setting for 10 weeks
Number of subjects: 24
Study 17517798 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary stenting in patients with mild to moderate CKD
Number of subjects: 1228
Study 17517798 — intervention group
Group type: COMPARATOR
Intervention: Coronary stenting in patients without CKD
Number of subjects: 1228
Study 15677778 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg once daily and lisinopril 20 mg once daily
Number of subjects: 75
Study 15677778 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 40 mg once daily
Number of subjects: 75
Study 12216507 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative ketamine (0.15 mg/Kg i.v.)
Number of subjects: 69
Study 12216507 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative ketamine (0.15 mg/Kg i.v.)
Number of subjects: 69
Study 12216507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 9640215 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy
Number of subjects: 1036
Study 9640215 — intervention group
Group type: COMPARATOR
Intervention: Tumorectomy plus radiotherapy
Number of subjects: 1036
Study 9640215 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 1036
Study 8018443 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour small-group intervention
Number of subjects: 148
Study 8018443 — intervention group
Group type: COMPARATOR
Intervention: Written materials about AIDS
Number of subjects: 148
Study 2730122 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated, water filled mattress kept at 37 degrees C (n = 28)
Number of subjects: 60
Study 2730122 — intervention group
Group type: COMPARATOR
Intervention: Air heated incubators with a mean air temperature of 35 degrees C (n = 32)
Number of subjects: 60
Study 5662989 — intervention group
Group type: EXPERIMENTAL
Intervention: Fried onions (60 g)
Number of subjects: 22
Study 5662989 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled onions (60 g)
Number of subjects: 22
Study 5662989 — intervention group
Group type: COMPARATOR
Intervention: Fat-enriched breakfast without onions
Number of subjects: 22
Study 30633744 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally‐Tailored Smoking Cessation plus Adherence Enhancement (CT+AE)
Number of subjects: 25
Study 30633744 — intervention group
Group type: EXPERIMENTAL
Intervention: Culturally‐Tailored Smoking Cessation (CTSC)
Number of subjects: 25
Study 30633744 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 25
Study 28062272 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic Risk Score (GRS)
Number of subjects: 0
Study 28062272 — intervention group
Group type: COMPARATOR
Intervention: Conventional Risk Score (CRS)
Number of subjects: 0
Study 27138185 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC-1002 120 mg
Number of subjects: 134
Study 27138185 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC-1002 180 mg
Number of subjects: 134
Study 27138185 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 134
Study 22713361 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 19
Study 22713361 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 23048056 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (10 mg/day)
Number of subjects: 32